drugs in other non-malignant conditions.
In the past 2 years 14 patients at the Institute of Ophthalmology have been treated with chlorambucil. This report is concerned with the preliminary findings in this group of patients.
Chlorambucil was chosen for its relatively low toxic/therapeutic ratio, and its selective depression of lymphocytes (de Gruchy, 1970) . The choice was encouraged by the experience of others who had used chlorambucil (Mamo and Azzam, 1970 Support for the antigenic role of uveal pigment in sympathetic ophthalmitis and Vogt-Koyanagi-Harada disease was advanced by Hammer (1971) in his work on lymphocyte transformation in patients with these conditions. Feinberg, Shore, Leopold, and Henley (1972) demonstrated leucocyte migration inhibition by an aqueous extract of uveal tissue in II of I2 patients with uveitis, although Strandgaard and Braendstrup (I 97 I) had previously failed to show this in 22 patients. Bonnet, Mouriquand, Jolbert, and Laurent (I 97 I) demonstrated the failure of aqueous in patients with relapsing uveitis to activate their own lymphocytes, and inferred from this the existence of cellular autoantibodies.
Several studies show the existence of antimucosal antibodies in the serum of patients with Behcet's disease during relapses (Oshima, Shimizu, Yokohari, Matsumoto, Kano, Kagami, and Nagaya, I963; Lehner, I967) . However, similar changes have been found in patients with aphthous ulcers alone. Shimizu, Katsuta, and Oshima (I965) showed increased reactivity in Behcet's disease to heat-aggregated human gamma-globulin, and their immunofluorescent studies showed responses with Behset's sera similar to those seen in certain collagen diseases.
There are many points at which immunological mechanisms may play a part in the pathogenesis of ocular disease, but the subject is at present still highly speculative. Much of our thinking derives by analogy from advances made in the understanding of other diseases in which the eye may be involved.
Work on the role of immune complexes in producing vascular damage with subsequent inflammation proceeds apace in systemic medicine, but the importance of this in the eye is conjectural. Nor does the presence of such complexes prove their complicity, as was well shown by Parish (I97 Ia, b) in his studies of cutaneous vasculitis. Parish found antigens of several bacteria in cutaneous vascular lesions, sometimes combined with immunoglobulin, indicating the formation of complexes, but in only one instance was the immunoglobulin demonstrated to be antibacterial antibody. Although there was indirect evidence of complex formation in these patients, specific antibacterial antibody commonly found in their sera rarely combined with the antigen in the lesion. In further studies on patients developing cutaneous vasculitis after streptococcal pharyngeal infections, Parish (I97i b) found that antibodies formed to streptococcal antigens in these patients had no particular ability to form tissue-damaging complexes when compared with antibody from patients with similar infections who did not develop vasculitis.
Antifolates
The example of this group is methotrexate. Toxicity is high. Mouth ulcers, nausea and vomiting, bowel disorders, and liver damage are common. Severe bone-marrow depression, with particular effect on the platelets, alopecia, and dermatitis may occur; it also severely interferes with embryogenesis. Antipurines 6-mercaptopurine, and its imidazole derivative azathioprine, have been used in uveitis. The latter has a better therapeutic/toxic ratio than 6-mercaptopurine.
Mason, Currey, Barnes, Dunne, Hazleman, and Strickland (I969) have found it useful in sparing steroid in rheumatoid arthritis, but its greatest use is in suppressing homograft rejection after transplant surgery. Its side-effects include bone-marrow depression and muscle atrophy. Although it is teratogenic, it does not appear to produce infertility.
Nitrogen mustards Cyclophosphamide and chlorambucil have a fairly well established place in the management of the minimal-change nephrotic syndrome in childhood. Cyclophosphamide produces chromosomal damage and sterility (Fairley, Barrie, and Johnson, I972; Uldall, Kerr, and Tacchi, I972), as well as bonemarrow depression. Haemorrhagic cystitis is often troublesome.
Chlorambucil, on the other hand, rarely produces anaemia and thrombocytopenia and it depresses lymphocytes rather more than polymorphs. Chromosomal damage has been reported. The question of its effect on fertility is not settled. Although Jackson, Fox, and Craig (I959) and Fox and Fox (I967) found that the aryl-substituted mustards did not affect the fertility of male rats, Richter, Calamera, Morgenfeld, Kierszenbaum, Lavieri, and Mancini (1970) reported azoospermia in eight patients treated for malignant lymphoma. The daily dose was generally higher than that which has been used in uveitis, although the total dose was not necessarily so.
Besides those undesirable side-effects mentioned above, there are possible long-term hazards the importance of which is not yet fully assessed. The most serious is the risk of inducing tumours. Penn, Halgrinson, and Starzl (I97I) reported an incidence of 6 per cent in 236 patients with renal transplants, and o-os8 per cent in a general population of similar age. All their patients were taking prednisolone and azathioprine. The recognition of the importance of immunological surveillance in tumour growth makes this finding less surprising-that is, if the drug is working as an immunosuppressive and not exerting its therapeutic action by some other means.
It is probable that many of these agents have a powerful anti-inflammatory effect, and previous workers have commented on the presence of a therapeutic effect without evidence of immunological depression (Newell and Krill, i967; Hersh, Wong, and Freireich, I966;  Buckley and Gills, I969).
Previous reports Hersh and others (i966), writing on the inhibition of local inflammatory response by antimetabolites, mentioned I3 patients with uveitis who were having methotrexate. They recorded in detail their experience with six of these patients (Wong and Hersh, i965) , all with pars planitis. Despite improvement while on treatment, five of the six had a recurrence within 2 to i8 weeks of stopping the treatment. Two responded to a second full course. The mononuclear response was suppressed, but there was no effect on the secondary antigenic response. Four patients showed evidence of liver toxicity.
The first report of the use of azathioprine was made by Bignell and Mackay (i967), who were unable to draw any conclusions about its efficacy in 20 patients with chronic uveitis. Newell and Krill (i967) were more hopeful, and reported improvements lasting up to I year in patients with pars planitis. Toxic reactions were less than they had previously experienced with 6-mercaptopurine, and they were able to reduce steroid dosage.
Rosselet, Saudan, and Zenklusen (I968) used azathioprine in three patients with Behcet's disease, and the most satisfactory result was an improvement in extraocular symptoms. Aoki, Fujioka, and Saito (197i) In the early part of the trial three patients (3, II, and I2) were given chlorambucil io mg daily, but subsequently dosage started at 5 mg daily and was reduced to 5 mg every other day after several months. Concomitant attempts were made to reduce the amount of steroid the patients were taking. Treatment was given for about 9 months, except for two patients on IO mg daily who took it for only 4 months.
A beneficial result was recorded if the ocular or the general condition improved, or if a substantial reduction in steroid dose could be made.
Results
In Table I the findings are summarized; in Table II they are presented in detail. reduction in steroid dose has yet been made. Patient 9 should also perhaps be included in the 'improved' category. He had hypopyon I month after beginning treatment, but has had no flare-up in the subsequent 13 months. He feels much better than he has for many years. He has been off chlorambucil for only 3 months, and steroids have been reduced only a little although they are continuing to be gradually reduced so far without ill-effect. However, in the past he has gone up to I year without ocular or systemic flare-up of his disease.
Patient 7 is in the middle of her course. She feels her vision is less misty, and we have reduced her steroid dose substantially, but it is too soon to draw a conclusion except to say that the response is favourable so far. Patient I I had no ocular flare-up during 13 months of treatment, and for IO months afterwards, when he had a small hypopyon. He is taking the lowest steroid dose since he began steroids I I years ago. The recent hypopyon settled rapidly when the steroids were increased for 2 weeks. In summary, the most impressive results were in Behcet's disease, and two of three patients with chronic generalized uveitis benefited largely in the reduction in steroid dosage that was possible. The patients with Behcet's disease became almost completely free of vascular and ulcerative lesions. Visual improvement in these patients was hardly to be expected, as their acuities had deteriorated to such low levels long before the drug was begun.
Toxicity Anaemia was not encountered. In only two patients did the white cell count fall below 4000/mm3. In four others it was reduced to 4000/mm3.
One patient developed thrombocytopenia (less than IOO 000 platelets/mm3) but responded to temporary withdrawal of treatment. Another patient complained of bruising, but this was due to mechanical trauma. A thorough investigation of his bleeding and clotting function was normal.
In one man with severe rheumatoid sclero-uveitis (who was under treatment elsewhere and is not included in this series), thrombocytopenia developed within 3 weeks of beginning treatment. He had had unexplained thrombocytopenia in the past and it was not felt that treatment with chlorambucil should be reintroduced.
One patient had a crop of boils, which cleared when the drug was withdrawn. Another developed a hordeolum when her white cell count was 4000/mm3.
One patient complained that the drug made him feel nauseated and depressed. He was taking IO mg daily.
Lymphocyte changes Most patients had a marked reduction in the total white cell count and lymphocyte count. The percentage of lymphocytes in the total white cell count was reduced in about half (Table III) . Total count reduced to less than half pretreatment level 8
Fall in percentage of white cell count of onethird or more 5
Of the I 2 patients to whom the Table applies, five are considered to have benefited from treatment, and we are reserving judgement in two. Four of the former (three of whom had Behset's disease) and one of the latter (also with Behset's disease) had lymphocyte counts reduced to less than half the pre-treatment levels.
These figures are presented simply for comparison with the findings of others. They illustrate the tendency of chlorambucil to produce relatively more lymphopenia than neutropenia.
Cytogenetic effects Lymphocyte cultures after treatment were studied by Dr Sylvia Lawler of the Department of Immunology and Cytogenetics at the Royal Marsden Hospital. Chromosomal changes of doubtful significance were found in two of io patients. One of these had had Io mg daily and the other had been unsuccessfully treated 2 years before with cyclophosphamide. Snaith, Holt, Oliver, Dunnill, Halley, and Stephenson (I973) reported findings in patients with systemic lupus erythematosus and nephritis. Of io patients treated with chlorambucil, none showed chromosomal damage, whereas damage was evident in five out of Io patients treated with cyclophosphamide.
Discussion
The status of immunosuppressives in non-malignant conditions has been reviewed by Lessof (I973). When drugs so potentially toxic as these are used, it is essential to define the type of case likely to benefit from treatment. Despite wide experience with large numbers of patients, physicians are largely undecided about the part these drugs should play in the treatment of conditions in which immunological mechanisms may be disordered. Their experience should make us doubly cautious in drawing conclusions from the small number of cases so far treated for eye disease.
Only in the case of Behcet's disease does a clearer role appear to be emerging, but one cannot yet say that treatment will make a permanent impression on the course of the disease. The improvement in systemic symptoms noted by some of our patients has also been commented on by Mamo and Azzam (1970) and Rosselet and others (I968) . Our preliminary findings with chronic generalized uveitis, and uveitis with vasculitis, are also mildly encouraging. It is intended to make a further report on this group of patients in i8 months' time. Ideally, double-blind trials might be attempted, but the practical difficulties of doing this are overwhelming.
Chlorambucil is probably one of the least dangerous of these agents. However, our ignorance about long-term side-effects, together with the inconclusiveness of published therapeutic findings, would deter one from using it indefinitely, or in repeated courses, in any one patient.
Serious short-term side-effects were uncommon in our patients. Leucopenia of less than 4000/mm3 was encountered in only two patients, one of whom was on a higher dose than we subsequently used, as was the patient who stopped his treatment because of nausea and depression. Although thrombocytopenia is uncommon, its occurrence in one patient highlights the importance of including platelet counts in the regular blood examination.
Until the incidence of long-term side-effects is better understood, we should limit the duration of treatment. Six months would probably have been adequate at the dose level used in most of our patients.
In Behset's disease we should be prepared to give the drug early in the disease, rather than to await the inexorable decline. All our patients had suffered visual deterioration to 6/6o or less before they began taking chlorambucil.
In conclusion we should remind ourselves that these drugs have only recently masqueraded under the title of 'immunosuppressives'. They were once known as antimetabolites and cytotoxic agents. They have not changed by acquiring a new name.
Nevertheless, a continuing cautious approach to their use in serious uveitis where other means of treatment have failed would appear to be justified by the experience so far obtained with them. 
